12,000 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by Premier Path Wealth Partners LLC

Premier Path Wealth Partners LLC bought a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 12,000 shares of the company’s stock, valued at approximately $126,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ROIV. FNY Investment Advisers LLC purchased a new stake in Roivant Sciences during the 4th quarter valued at approximately $33,000. Headlands Technologies LLC purchased a new stake in Roivant Sciences during the 4th quarter valued at approximately $36,000. Allspring Global Investments Holdings LLC purchased a new stake in Roivant Sciences during the 3rd quarter valued at approximately $44,000. Covestor Ltd grew its holdings in Roivant Sciences by 165,040.0% during the 3rd quarter. Covestor Ltd now owns 8,257 shares of the company’s stock valued at $96,000 after buying an additional 8,252 shares in the last quarter. Finally, Capstone Investment Advisors LLC purchased a new stake in Roivant Sciences during the 4th quarter valued at approximately $170,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Roivant Sciences Trading Up 0.5 %

ROIV traded up $0.06 during trading on Wednesday, reaching $11.29. The company had a trading volume of 4,722,291 shares, compared to its average volume of 6,179,250. The stock has a market cap of $9.10 billion, a P/E ratio of 2.17 and a beta of 1.30. The business has a 50 day simple moving average of $10.90 and a 200-day simple moving average of $10.62. Roivant Sciences Ltd. has a 52 week low of $8.24 and a 52 week high of $13.24. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Wolfe Research assumed coverage on shares of Roivant Sciences in a report on Thursday, February 15th. They set an “outperform” rating and a $17.00 price objective for the company. Truist Financial reiterated a “buy” rating and set a $23.00 target price on shares of Roivant Sciences in a research report on Monday, March 25th. Deutsche Bank Aktiengesellschaft increased their target price on Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research report on Monday, April 22nd. Finally, The Goldman Sachs Group increased their target price on Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.90.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.